Perceptive Advisors portfolio · Q4 2025
Perceptive Advisors LLC · CIK 0001224962 ·13F filings on SEC EDGAR
In Q4 2025, Perceptive Advisors LLC reported 116 positions worth $5.6B. Its largest holding was PRAX at 10.5% of the portfolio, and the top 10 made up 42%. This is the earliest quarter available here, so changes are not shown.
Portfolio map
Each box is a position sized by its value. There is no previous quarter here to compare changes. The smallest 76 positions are grouped as one box.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
PRAX PRAXIS PRECISION MEDICINES I | 10.49% | $108.62 | $291.23 | +168.1% | $581.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CELC CELCUITY INC | 5.62% | $36.00 | $79.52 | +120.9% | $251.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 4.86% | $100.66 | $95.22 | -5.4% | $242.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
04351P101 ASCENDIS PHARMA A/S | 4.11% | $175.60 | $228.73 | +30.3% | $247.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
APGE APOGEE THERAPEUTICS INC | 3.14% | $48.89 | $132.73 | +171.5% | $309.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 3.09% | $14.03 | $36.57 | +160.7% | $292M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 2.99% | $51.19 | $123.50 | +141.2% | $205.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TVTX TRAVERE THERAPEUTICS INC | 2.91% | $23.74 | $58.88 | +148.0% | $251.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XBIPut SS SPDR S&P BIOTECH ETF | 2.39% | — | — | — | $134.1M |
EXAS EXACT SCIENCES CORP | 2.17% | $109.65 | $101.56 | -7.4% | $121.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTGX PROTAGONIST THERAPEUTICS INC | 2.10% | $43.67 | $140.89 | +222.6% | $190.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INBX INHIBRX BIOSCIENCES INC | 2.05% | $24.45 | $100.08 | +309.4% | $145.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 1.97% | $21.59 | $40.60 | +88.0% | $181M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMTX IMMATICS NV | 1.94% | $10.71 | $8.78 | -18.0% | $91.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 1.79% | $28.28 | $89.03 | +214.8% | $273.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 1.78% | $4.78 | $29.10 | +508.6% | $241.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACLX ARCELLX INC | 1.70% | $27.37 | $114.82 | +319.5% | $168.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 1.69% | $26.42 | $20.59 | -22.1% | $62.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSX BOSTON SCIENTIFIC CORP | 1.66% | $98.00 | $43.65 | -55.5% | $42.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FOLD AMICUS THERAPEUTICS INC | 1.62% | $10.50* | $14.46 | +37.7% | $92.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZYME ZYMEWORKS INC | 1.53% | $17.30 | $26.49 | +53.2% | $86.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ATXS ASTRIA THERAPEUTICS INC | 1.51% | $11.21 | $13.09 | +16.8% | $84.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGTX MEIRAGTX HOLDINGS PLC | 1.46% | $13.24 | $11.00 | -16.9% | $113.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AORT ARTIVION INC | 1.40% | $20.47 | $34.23 | +67.2% | $59M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTA CENTESSA PHARMACEUTICALS LTD | 1.30% | $20.01 | $39.72 | +98.5% | $115.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 1.21% | $19.08 | $16.11 | -15.5% | $56M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 1.20% | $16.38 | $23.71 | +44.7% | $84.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLDB SOLID BIOSCIENCES INC | 1.19% | $6.95 | $7.23 | +4.0% | $85.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BLTE BELITE BIO INC - ADR | 1.18% | $149.63 | $169.82 | +13.5% | $70.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABVX ABIVAX SA-ADR | 1.10% | $92.50 | $99.02 | +7.0% | $45.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVVD INVIVYD INC | 0.96% | $2.47 | $0.87 | -64.8% | $19M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
29286M105 ENGENE HOLDINGS INC | 0.94% | $8.24 | $6.81 | -17.4% | $40M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RGEN REPLIGEN CORP | 0.92% | $134.28 | $192.23 | +43.2% | $60.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 0.90% | $24.48 | $33.78 | +38.0% | $67.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ISRG INTUITIVE SURGICAL INC | 0.89% | $468.73 | $406.63 | -13.2% | $35.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 0.86% | $10.46 | $5.26 | -49.7% | $6.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NBIX NEUROCRINE BIOSCIENCES INC | 0.84% | $132.58* | $141.84 | +7.0% | $47M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DHR DANAHER CORP | 0.82% | $228.92 | $221.55 | -3.2% | $44.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 0.80% | $20.79 | $83.29 | +300.5% | $123M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.74% | $2.53 | $2.72 | +7.7% | $26.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OMDA OMADA HEALTH INC | 0.67% | $18.30 | $21.95 | +19.9% | $52.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CDTX CIDARA THERAPEUTICS INC | 0.65% | $220.89 | $220.89 | 0.0% | $36.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRON DISC MEDICINE INC | 0.64% | $79.41 | $65.46 | -17.6% | $29.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DRUG BRIGHT MINDS BIOSCIENCES INC | 0.62% | $37.59 | $49.82 | +32.5% | $22.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEN PENUMBRA INC | 0.61% | $253.81 | $318.34 | +25.4% | $35.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANRO ALTO NEUROSCIENCE INC | 0.57% | $16.60 | $25.53 | +53.8% | $45.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAI CARIS LIFE SCIENCES INC | 0.55% | $26.73 | $30.63 | +14.6% | $34.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JAZZ JAZZ PHARMACEUTICALS PLC | 0.52% | $170.00 | $231.52 | +36.2% | $39.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.50% | $2.35 | $1.35 | -42.6% | $16.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RAPT RAPT THERAPEUTICS INC | 0.50% | $28.11 | $33.87 | +20.5% | $28M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PVLA PALVELLA THERAPEUTICS INC | 0.50% | $62.69 | $137.93 | +120.0% | $36.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AXSM AXSOME THERAPEUTICS INC | 0.48% | $81.65 | $184.39 | +125.8% | $27.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AXGN AXOGEN INC | 0.46% | $32.73 | $41.92 | +28.1% | $32.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XFOR X4 PHARMACEUTICALS INC | 0.45% | $4.00 | $2.90 | -27.5% | $18.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 0.44% | $7.80 | $8.33 | +6.8% | $26.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAUT NAUTILUS BIOTECHNOLOGY INC | 0.44% | $6.31 | $1.42 | -77.5% | $17.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KOD KODIAK SCIENCES INC | 0.42% | $19.30 | $94.80 | +391.3% | $80.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIIB BIOGEN INC | 0.39% | $175.99 | $225.88 | +28.3% | $28M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALDX ALDEYRA THERAPEUTICS INC | 0.39% | $4.91* | $5.18 | +5.6% | $21.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OBIO ORCHESTRA BIOMED HOLDINGS IN | 0.38% | $10.64 | $6.22 | -41.6% | $31.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.37% | $78.99 | $85.48 | +8.2% | $22.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RAPP RAPPORT THERAPEUTICS INC | 0.36% | $29.96 | $33.60 | +12.2% | $22.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GRAL GRAIL INC | 0.36% | $85.59 | $140.12 | +63.7% | $33.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRTC IRHYTHM HOLDINGS INC | 0.34% | $171.99 | $113.66 | -33.9% | $12.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBNX BETA BIONICS INC | 0.33% | $22.07 | $18.98 | -14.0% | $11.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CVS CVS HEALTH CORP | 0.31% | $79.36 | $85.69 | +8.0% | $18.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.30% | $14.38 | $13.42 | -6.7% | $19.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GH GUARDANT HEALTH INC | 0.29% | $102.14 | $178.36 | +74.6% | $28.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADMA ADMA BIOLOGICS INC | 0.29% | $8.43 | $10.03 | +19.0% | $8.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 0.29% | $8.46 | $18.05 | +113.4% | $34.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GKOS GLAUKOS CORP | 0.28% | $112.91 | $164.19 | +45.4% | $23M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DXCM DEXCOM INC | 0.27% | $66.37 | $86.29 | +30.0% | $19.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SVRA SAVARA INC | 0.26% | $6.03 | $5.16 | -14.4% | $12.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.25% | — | — | — | $14.1M | |
LONA LEONABIO INC | 0.25% | $6.49 | $3.57 | -45.0% | $6.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 0.22% | $10.57 | $39.13 | +270.2% | $16.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IKT INHIBIKASE THERAPEUTICS INC | 0.20% | $3.25 | $2.06 | -36.8% | $11.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADGM ADAGIO MEDICAL HOLDINGS INC | 0.18% | $2.57 | $0.15 | -94.1% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OCS OCULIS HOLDING AG | 0.18% | $19.97 | $9.34 | -53.2% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
38341P102 GOSSAMER BIO INC | 0.17% | $2.63 | $0.16 | -93.7% | $516.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MPLT MAPLIGHT THERAPEUTICS INC | 0.17% | $17.56 | $10.19 | -42.0% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XENE XENON PHARMACEUTICALS INC | 0.16% | $34.75 | $37.19 | +7.0% | $7.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRD OPUS GENETICS INC | 0.15% | $0.98 | $4.84 | +393.0% | $20.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 0.15% | $5.58 | $7.77 | +39.2% | $13M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KMTS KESTRA MEDICAL TECHNOLOGIES | 0.13% | $26.52 | $26.52 | 0.0% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.12% | — | — | — | $7M | |
BLLN BILLIONTOONE INC CL A | 0.11% | $81.84 | $106.44 | +30.1% | $7.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.10% | — | — | — | $5.6M | |
KYMR KYMERA THERAPEUTICS INC | 0.10% | $43.64 | $111.79 | +156.2% | $7.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEPG PEPGEN INC | 0.10% | $4.62 | $2.42 | -47.6% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBIO CRESCENT BIOPHARMA INC | 0.10% | $16.14 | $14.59 | -9.6% | $6.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TENX TENAX THERAPEUTICS INC | 0.10% | $12.19 | $56.70 | +365.1% | $24.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRVS CORVUS PHARMACEUTICALS INC | 0.10% | $4.00 | $11.52 | +188.0% | $8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.09% | — | — | — | $5.2M | |
AQST AQUESTIVE THERAPEUTICS INC | 0.09% | $4.02 | $4.15 | +3.2% | $3.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNGX TANGO THERAPEUTICS INC | 0.08% | $8.86 | $24.95 | +181.6% | $12.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRYS KRYSTAL BIOTECH INC | 0.08% | $176.53 | $332.56 | +88.4% | $5.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COGT COGENT BIOSCIENCES INC | 0.08% | $35.52 | $32.02 | -9.9% | $3.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OLMA OLEMA PHARMACEUTICALS INC | 0.07% | $25.00 | $8.64 | -65.4% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SDGR SCHRODINGER INC | 0.06% | $17.88 | $31.05 | +73.7% | $6.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OM OUTSET MEDICAL INC | 0.06% | $11.06 | $3.00 | -72.9% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SABS SAB BIOTHERAPEUTICS INC | 0.05% | $3.74 | $3.17 | -15.2% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTX AVALO THERAPEUTICS INC | 0.05% | $8.01 | $15.33 | +91.4% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTB CONNECT BIOPHARMA HOLDINGS L | 0.04% | $2.82 | $1.10 | -61.0% | $872K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMMX IMMIX BIOPHARMA INC | 0.03% | $5.23 | $9.11 | +74.2% | $3.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXEO LEXEO THERAPEUTICS INC | 0.02% | $9.04 | $3.38 | -62.6% | $472.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CPIX CUMBERLAND PHARMACEUTICALS | 0.02% | $3.98 | $3.24 | -18.6% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDLN MEDLINE INC-CL A | 0.02% | $42.00 | $34.70 | -17.4% | $971.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTN PALATIN TECHNOLOGIES INC | 0.02% | $15.38 | $8.87 | -42.3% | $620.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LENZ LENZ THERAPEUTICS INC | 0.01% | $16.00 | $3.84 | -76.0% | $192K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BDSX BIODESIX INC | 0.01% | $7.55 | $22.55 | +198.7% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
29415J106 ENVVENO MEDICAL CORPORATION | 0.01% | $3.16 | $0.32 | -89.8% | $564.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IOVA IOVANCE BIOTHERAPEUTICS INC | 0.01% | $2.73 | $14.82 | +442.9% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMDW REVOLUTION MEDICINES INC-28 | 0.00% | $0.33 | $11.44 | +3,366.7% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENSC ENSYSCE BIOSCIENCES INC | 0.00% | $8.14 | $0.42 | -94.9% | $36K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZNW SURROZEN INC-CW25 | 0.00% | — | $0.02 | — | $2.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Mar 31, 2016, when our collected history starts, so the average starts from that quarter's price.
SEC filings for Q4 2025
- 13F-HR 0001012975-26-000155 · accepted Feb 17, 2026, 21:10 UTC